CorMedix stock drops after earnings: is this dip a buy before key catalyst?

CorMedix (NASDAQ: CRMD) opened meaningfully down on March 5th after reporting a massive swing to profitability but reaffirming 2026 guidance that failed to impress shareholders.

The biopharmaceutical firm said its revenue came in at a robust $129 million in the fourth quarter, but guided for $310 million for the full year – representing a slight deceleration versus 2025.

However, for the discerning investor, this post-earnings slump offers strategic entry into CorMedix stock before several major catalysts unfold in the months ahead.  

Should you buy the post-earnings dip in CorMedix stock?

While the full-year outlook fell short of some aggressive estimates, CRMD stock has entered 2026 in a position of unprecedented financial strength.

The Nasdaq-listed firm ended last year with nearly $149 million in cash and short-term investment, a war chest that’s allowed the board to authorise a $75 million share repurchase programme.

This buyback is a dual-purpose tool: it signals management’s firm belief that CorMedix is currently undervalued while offering a mechanism to combat the persistent short interest that’s “dogging” its share price.

By reducing the float, CRMD is tightening the spring for a potential recovery as the company turns cash flow positive.  

What could drive CRMD shares higher in 2026?

The current bearish sentiment ignores a massive binary event scheduled for the second quarter: the release of late-stage data for CRMD’s next-gen anti-fungal medication – REZZAYO.

This trial evaluates the treatment’s efficacy in preventing invasive fungal diseases in bone marrow transplant patients, a market segment desperate for options with fewer drug-to-drug interactions.

Positive Phase III data wouldn’t just validate the firm’s recent Melinta acquisition, but also unlock a new, high-margin revenue stream.

Investors buying the dip in CorMedix shares today are essentially gaining exposure to this “multi-billion-dollar market” opportunity at a discount – as the market’s focus unfairly remains fixed on temporary price erosion expected during the DefenCath reimbursement transition later in 2026.

CorMedix is attractively valued at writing

Finally, investors must also realize that CorMedix’s conservative guidance, in management’s own words, excludes “any potential upside” from new customer partnerships or “Medicare Advantage” contracting.

CRMD is currently in active discussions with multiple providers to expand DefenCath’s reach.

Additionally, the company is aggressively pursuing the total parenteral nutrition (TPN) market – with a Phase III study currently enrolling.

By diversifying DefenCath’s application beyond the outpatient dialysis clinic, CorMedix is building a resilient, multi-pronged commercial engine.

If management secures even one major new hospital system or national provider partnership in the coming months, the current “conservative” guidance could quickly become obsolete, leaving those who sold on the news chasing a rapidly rising stock.

Note that CRMD shares are currently trading at a price-to-sales (P/S) multiple of about 2.4x, which means they are not particularly expensive to own for a long-term investor.